- Home
- GRND vs NVAX Comparison
GRND vs NVAX Comparison
Compare GRND & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- NVAX
- Stock Information
- Founded
- GRND 2009
- NVAX 1987
- Country
- GRND United States
- NVAX United States
- Employees
- GRND N/A
- NVAX N/A
- Industry
- GRND Computer Software: Prepackaged Software
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRND Technology
- NVAX Health Care
- Exchange
- GRND Nasdaq
- NVAX Nasdaq
- Market Cap
- GRND 2.1B
- NVAX 2.0B
- IPO Year
- GRND N/A
- NVAX 1995
- Fundamental
- Price
- GRND $13.65
- NVAX $9.76
- Analyst Decision
- GRND Strong Buy
- NVAX Buy
- Analyst Count
- GRND 3
- NVAX 6
- Target Price
- GRND $15.33
- NVAX $17.83
- AVG Volume (30 Days)
- GRND 464.9K
- NVAX 7.2M
- Earning Date
- GRND 11-07-2024
- NVAX 11-07-2024
- Dividend Yield
- GRND N/A
- NVAX N/A
- EPS Growth
- GRND N/A
- NVAX N/A
- EPS
- GRND N/A
- NVAX N/A
- Revenue
- GRND $300,034,000.00
- NVAX $987,667,000.00
- Revenue This Year
- GRND $30.64
- NVAX N/A
- Revenue Next Year
- GRND $21.70
- NVAX N/A
- P/E Ratio
- GRND N/A
- NVAX N/A
- Revenue Growth
- GRND 34.98
- NVAX N/A
- 52 Week Low
- GRND $5.71
- NVAX $3.53
- 52 Week High
- GRND $13.90
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- GRND 63.17
- NVAX 36.20
- Support Level
- GRND $13.06
- NVAX $9.52
- Resistance Level
- GRND $13.90
- NVAX $10.63
- Average True Range (ATR)
- GRND 0.42
- NVAX 0.57
- MACD
- GRND 0.06
- NVAX -0.12
- Stochastic Oscillator
- GRND 80.54
- NVAX 9.97
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.